MLTX
MoonLake Immunotherapeutics
NASDAQ · Healthcare · Biotechnology · CH
$9.75
+2.09%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-61.6%
Return on equity
-45.9%
Return on assets
-50.7%
Return on invested capital
0.00x
Asset turnover
-$225.2M
Cash from operations
$6.31
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026